Checkpoint Therapeutics Inc. (CKPT), a clinical-stage immunotherapy and targeted oncology company, is making a second attempt to get FDA approval for its lead drug candidate Cosibelimab.
Cosibelimab, an anti-programmed death ligand-1 ("PD-L1") antibody, is being developed for patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation.
For comments and feedback contact: editorial@rttnews.com
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.